Achieving a one-year-tumor-free survival in a female with primary large cell neuroendocrine carcinoma of the urinary bladder and liver metastasis; a case report

Primary neuroendocrine tumor (NET) of bladder is rare. It has four subtypes, and large cell neuroendocrine carcinoma (LCNEC) is the rarest. LCNEC affects mostly men over 60. Most common symptom is gross hematuria. It has no specific treatment. Metastasis is common and once occurred, average survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoudnejad, Nastaran, Mohammadi Torbati, Peyman, Lashay, Alireza, Ahmadi, Navid, Guitynavard, Fateme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931890/
https://www.ncbi.nlm.nih.gov/pubmed/36816609
http://dx.doi.org/10.1016/j.eucr.2023.102347
Descripción
Sumario:Primary neuroendocrine tumor (NET) of bladder is rare. It has four subtypes, and large cell neuroendocrine carcinoma (LCNEC) is the rarest. LCNEC affects mostly men over 60. Most common symptom is gross hematuria. It has no specific treatment. Metastasis is common and once occurred, average survival would be less than three months. Herein we present diagnostic and therapeutic management of a 65-year-old female with LCNEC of bladder and concurrent high-grade urothelial carcinoma. Despite developing early liver metastasis, she achieved a one-year tumor-free survival.

Ejemplares similares